| Autor: |
Yamazhan T, Kurtaran B, Pullukçu H, Yüksel E, Özkaya D, Taşbakan MI, Sipahi OR, Durusoy R, Aksu HS |
| Jazyk: |
angličtina |
| Zdroj: |
Journal of chemotherapy (Florence, Italy) [J Chemother] 2014 Dec; Vol. 26 (6), pp. 339-41. Date of Electronic Publication: 2013 Dec 06. |
| DOI: |
10.1179/1973947813Y.0000000152 |
| Abstrakt: |
In this study, we aimed to evaluate the 1-year post-treatment follow-up results of 112 patients who received pegylated interferon (PEG-IFN) for 52 weeks. HBeAg negativity/seroconversion and/or negative HBV-DNA at the end of the treatment were considered as response. Patients who had response at the end of treatment but had HBV-DNA breakthrough during 1-year follow-up were considered as relapse. The study group comprised 112 cases (34 HBeAg-positive, 78 HBeAg-negative). In HBeAg-positive and -negative cases, end-of-treatment response rates were 2·9% and 60·2%, whereas 1-year sustained virological response rates were 0 and 33·3%, respectively. When we compared relapse cases versus cases with response at the end of 1-year follow-up, being female and having low viral load were the two parameters associated with higher response rates (Chi-square, P = 0·028; Mann-Whitney U test, P = 0·023). Overall non-response rates to PEG-IFN were high (57·1%). Results in HBeAg-positive cases were disappointing. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
